Application of Modified Mupit for the Recurrent Vulva Cancer in Brachytherapy

재발한 Vulvar 종양의 근접치료 시 Modified Mupit Applicator의 적용

  • Kim, Jong-Sik (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Jung, Chun-Young (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Oh, Dong-Gyoon (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Song, Ki-Won (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Park, Young-Hwan (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 김종식 (삼성서울병원 방사선종양학과) ;
  • 정천영 (삼성서울병원 방사선종양학과) ;
  • 오동균 (삼성서울병원 방사선종양학과) ;
  • 송기원 (삼성서울병원 방사선종양학과) ;
  • 박영환 (삼성서울병원 방사선종양학과)
  • Published : 2006.03.31

Abstract

Purpose: To evaluate whether modified MUPIT applicator can effectively eradicate recurrent tumor in uterine cervix cancer and reduce rectal complication after complete radiation treatment. Materials and Methods: Modified MUPIT applicator basically consists of an acrylic cylinder with flexible brain applicator, an acrylic template with a predrilled array of holes that serve as guides for interstitial needles and interstitial needles. CT scan was peformed to determine tumor volume and the position of interstitial needles. Modified MUPIT applicator was applied to patient in operation room and the accuracy for position of interstitial needles in tumor volume was confirmed by CTscan. Brachytherapy was delivered using modified MUPIT applicator and RALS(192-lr HDR) after calculated computer planning by orthogonal film. The daily dose was 600cGy and the total dose was delivered 3,000 cGy in tumor volume by BID. Rectal dose was measured by TLD at 5 points so that evaluated the risk of rectal complication. Results: The application of modified MUPIT applicator improved dramatically dose distributions in tumor volume and follow-up of 3 month for this patient was clinically partial response without normal tissue complication, Rectal dose was measured 34.1 cGy, 57.1 cGy, 103.8 cGy, 162.7 cGy, 165.7 cGy at each points, especially the rectal dose including previous EBRT and ICR was 34.1 cGy, 57.1 cGy. Conclusion: Patients with locally recurrent tumor in uterine cervix cancel treated with modified MUPIT applicator can expect reasonable rates of local control. The advantages of the system are the fixed geometry provided by the template and cylinders. and improved dose distributions in irregular tumor volume without rectal complication.

목 적: 재발한 vulva 종양의 근접 치료 시 정상조직의 장애와 종양 체적 내의 선량 균등도를 개선하기 위해 modified MUPIT applicator를 자체 고안하였으며 이에 대한 유용성을 평가하고자 한다. 대상 및 방법: Modified MUPIT applicator는 template, cylinder, interstitial needle로 구성 되었으며, 종양 체적을 정하기 위하여 치료 전 CT를 시행하였다. CT 영상을 이용하여 Interstitial needle의 삽입 위치를 결정하고, 수술실에서 template를 치료 부위에 고정을 시키고, cylinder를 vaginal cavity에 삽입한 후, interstitial needle을 종양 체적 내에 삽입하였다. 삽입된 interstitial needle의 정확한 위치를 확인하기 위하여 확인용 CT를 시행하였으며, simulation을 통하여 얻어진 orthogonal film을 이용하여 치료 계획을 수립하였다. 일일 종양 선량은 600 cGy, BID로 3,000 cGy를 조사하였으며, 치료 시 직장 선량을 평가하기 위하여 TLD를 이용하여 anal verge를 기준으로 5개 지점에서의 직장 선량을 측정하였다. 결 과: Modified MUPIT applicator 대한 유용성을 평가하기 위하여 측정된 직장 선량은 34.1 cGy, 57.1 cGy, 103.8 cGy, 162.7 cGy, 165.7 cGy로 측정되었으며, 외부방사선치료(EBRT: External Beam Radiation Therapy), 강내방사선치료(ICR: Intracavitary radiotherapy)와 중첩되는 지점은 34.1 cGy, 57.1 cGy로 매우 우수하게 평가되었다. 결 론: 자체 제작한 modified MUPIT applicator 사용하여 조직 내 근접치료(Interstitial brachytherapy)를 시행함으로써, 외부방사선치료로 접근하기 어려운 종양에 대하여 선량 균등도를 효율적으로 개선할 수 있었고, 직장 선량을 최소화하여 직장의 부작용 발생 확률을 현저히 감소시킬 수 있었다.

Keywords